Cargando…
Revisiting Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients with Glioblastoma—Proteomic Alteration and Comparison Analysis with the Standard-of-Care Chemoirradiation
Background: Glioblastoma (GBM) is the most common brain tumor with an overall survival (OS) of less than 30% at two years. Valproic acid (VPA) demonstrated survival benefits documented in retrospective and prospective trials, when used in combination with chemo-radiotherapy (CRT). Purpose: The prima...
Autores principales: | Krauze, Andra V., Zhao, Yingdong, Li, Ming-Chung, Shih, Joanna, Jiang, Will, Tasci, Erdal, Cooley Zgela, Theresa, Sproull, Mary, Mackey, Megan, Shankavaram, Uma, Tofilon, Philip, Camphausen, Kevin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604983/ https://www.ncbi.nlm.nih.gov/pubmed/37892181 http://dx.doi.org/10.3390/biom13101499 |
Ejemplares similares
-
RadWise: A Rank-Based Hybrid Feature Weighting and Selection Method for Proteomic Categorization of Chemoirradiation in Patients with Glioblastoma
por: Tasci, Erdal, et al.
Publicado: (2023) -
Glioblastoma survival is associated with distinct proteomic alteration signatures post chemoirradiation in a large-scale proteomic panel
por: Krauze, Andra Valentina, et al.
Publicado: (2023) -
SDPS-29 SERUM-DERIVED CD47 AS A MARKER OF TUMOR BURDENAND OUTCOME IN GBM PATIENTS – CORRELATIVE ANALYSISOF TUMOR LOCATION, RADIATION THERAPY VOLUMES,AND SURVIVAL
por: Jagasia, Sarisha, et al.
Publicado: (2023) -
Chemoirradiation for Glioblastoma Multiforme: The National Cancer Institute Experience
por: Ho, Jennifer, et al.
Publicado: (2013) -
The Next Frontier in Health Disparities—A Closer Look at Exploring Sex Differences in Glioma Data and Omics Analysis, from Bench to Bedside and Back
por: Diaz Rosario, Maria, et al.
Publicado: (2022)